Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%

Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore

Thermo Fisher to expand dry powder media manufacturing facility in New York

With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies

Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market

Zydus receives final approval from the USFDA for Ivermectin Cream

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.

Poly Medicure Q1FY23 consolidated PAT drops to Rs. 26.96 Cr

The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

USFDA issues 3 observations for Aurobindo Pharma’s Unit XI

The company has responded to the warning letter and carried out the committed corrections.

Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr

The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.

Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma

The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.

PIB: Quality control of Ayush drugs